Back to Archived News
CyDex Pharmaceuticals Receives U.S. Patent for New Captisol
Wednesday, December 09, 2009
Improves Handling Characteristics of Captisol® in Liquid Formulations for Parenteral Administration and for Oral Solids
Lenexa, KS -- CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled "Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof." This patent, along with other previously issued technology patents, will provide broader protection for CyDex’s Captisol® technology until 2028.
The patent (U.S. Patent No. 7,629,331) grants protection for a new agglomerated beta cyclodextrin sulfobutyl ether sodium salt product known as Captisol. Captisol is CyDex’s proven enabling drug delivery technology that aids in the solubilization, stabilization and taste masking of active pharmaceutical ingredients.
"The Captisol that is protected by this patent flows better, dissolves faster, and packs more densely than previous morphologies," said Dr. Theron Odlaug, President and Chief Executive Officer of CyDex Pharmaceuticals, Inc. "These improved characteristics make Captisol easier to incorporate in liquids manufactured for parenteral administration. Our strategy is focused on licensing Captisol technology and developing our own products that target unmet needs in hospital intravenous therapy, where parenteral dosage forms are crucial. Consequently, this patent provides us with yet another competitive advantage in our core market. In addition, because the new morphology improves the suitability of Captisol in manufacturing oral drug dosage forms, receiving this patent enhances our ability to pursue opportunities beyond intravenous therapy."
Captisol is manufactured using a validated, patent-protected process and conforms to USP <1078> on Good Manufacturing Practices for Bulk Pharmaceutical Excipients.
About CyDex Pharmaceuticals, Inc.
CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company developing products and licensing its Captisol® technology. Captisol is currently incorporated in five FDA approved medications and marketed by three of the company’s licensees: Pfizer, Bristol-Myers Squibb and Prism Pharmaceuticals. In addition the company is supporting drug development efforts with more than 40 other companies worldwide. The company maintains patents in the U.S. and worldwide for its Captisol technology and Captisol enabled products, and comprehensive FDA Manufacturing and Safety Drug Master Files. For additional information on business development opportunities, please contact Richard White at firstname.lastname@example.org or 913.685.8850. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit www.cydexpharma.com.
Back to Archived News